Evolution of clinical and pathologic symptoms after Covid-19 infection. Post Covid-19 clinical and pathological structure of disease with new Sars-Covid-19-2 virus evolution treatment of human

      Аннотация: First cases COVID-19 in Wuhan China end 2019 then went to the world. Symptoms: Fever, cough, headache, fatigue, breathing difficulties and loss of taste transmitted by droplets particles from infected people. Lung organ most affected. Treatment: stopping cytokine storm leading cause of morbidity and mortality in COVID-19 disease. Vaccines prevented 14.4 to 19.8 deaths in 185 countries from 8 December 2020 to 8 December 2021. 18 June 2023 13.42 billion doses of COVID-19 have been given worldwide. Immune response to Sars-Covid-19-2 virus is a combination of cell mediated immunity and antibodies. Pandemic has resulted in 110 million confirmed infections with 2.4 million deaths worldwide in February 2021. August 6, 2023, confirm cases 552,695 with 5,856 deaths and 546,537 (96%) recuperated cases in Venezuela. In the world 768,982,331 with 6,953,730 deaths. Reactivated virus like Epstein-Barr-Virus (EBV), Human Herpesvirus-6 (HHV-6) have been found in patients with long COVID, viral persistence is a driver of long COVID symptoms, viral proteins and RNA, in the reproductive system, brain, eyes, muscles, cardiovascular system, lymph nodes, appendix, breast, hepatic, lung tissue.

Ключевые слова: COVID-19, Clinical Symptoms, pathology, RNA virus, Wuhan China, Sars-Covid-2, Cygokine stor, Bcells, T cells, peptides, vaccines, Neuropsychyatry